Kevzara Injection, Solution
Product Images NDC 0024-5910

53 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 53 technical images submitted to the FDA as part of the official labeling for Kevzara (NDC 0024-5910). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (827bc01c D379 4266 A18c C7f904b76af3 01)

Figure 1 (827bc01c D379 4266 A18c C7f904b76af3 01)
A line graph illustrating the percentage of patients with ACR20 response over 24 study weeks. It compares three groups: Placebo + MTX, KEVZARA 150 mg + MTX, and KEVZARA 200 mg + MTX, showing responses increasing over time, with KEVZARA groups demonstrating higher response rates than placebo.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01a)

Image (827bc01c D379 4266 A18c C7f904b76af3 01a)
An instructional diagram of a KEVZARA (sarilumab) prefilled syringe for subcutaneous injection. The labeled parts include the plunger, finger grip, label with expiry date, syringe body, needle cap, and needle tip shown in an enlarged circular inset below the syringe.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01b)

Image (827bc01c D379 4266 A18c C7f904b76af3 01b)
An instructional illustration depicting a hand removing or holding an injection pen device from a tray or packaging, likely related to a subcutaneous injection product. The tray includes a molded compartment designed to hold the pen securely.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01c)

Image (827bc01c D379 4266 A18c C7f904b76af3 01c)
The image shows a label for KEVZARA (sarilumab) injection solution with a strength of 150 mg/1.14 mL. The label indicates it is an Rx-only medication. A secondary view of the label includes barcode areas for lot number and expiration date. The product is labeled by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01d)

Image (827bc01c D379 4266 A18c C7f904b76af3 01d)
Illustration showing a vertical cross-sectional view of a cylindrical container or vial with a rounded bottom inside a circular frame. The container appears empty and is mostly transparent with a yellow line near the top edge.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01e)

Image (827bc01c D379 4266 A18c C7f904b76af3 01e)
Illustration of a KEVZARA (sarilumab) injection pen labeled 200 mg/1.14 mL, showing the pen design with a timer indicating a 30-minute duration, likely for administration or injection timing guidance.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01f)

Image (827bc01c D379 4266 A18c C7f904b76af3 01f)
Illustration showing recommended subcutaneous injection sites for KEVZARA (sarilumab) on a human body. Highlighted areas in orange indicate common injection locations on the upper arms, abdomen, and front thighs.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01g)

Image (827bc01c D379 4266 A18c C7f904b76af3 01g)
An instructional illustration showing a hand holding a prefilled syringe with an orange finger grip, removing the needle cap by pulling it straight off, indicated by an arrow pointing away from the syringe.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01h)

Image (827bc01c D379 4266 A18c C7f904b76af3 01h)
An illustration showing a hand gently pinching the skin on an arm, likely demonstrating a step for subcutaneous injection administration.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01i)

Image (827bc01c D379 4266 A18c C7f904b76af3 01i)
An instructional illustration demonstrating proper injection technique for subcutaneous administration. The image shows a hand holding a syringe at a 45-degree angle, preparing to inject into the skin of another hand.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01j)

Image (827bc01c D379 4266 A18c C7f904b76af3 01j)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) injection pen, with an arrow indicating the direction for administering the subcutaneous injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01k)

Image (827bc01c D379 4266 A18c C7f904b76af3 01k)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) injection pen, positioned for subcutaneous administration. The pen is labeled with KEVZARA and the dose 150 mg/1.14 mL, consistent with the approved dosage form as a subcutaneous injection solution by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01m)

Image (827bc01c D379 4266 A18c C7f904b76af3 01m)
Illustration showing a hand holding a KEVZARA prefilled syringe, positioned above a disposal container. The syringe cap is being removed and directed downward into the container, indicating proper syringe cap disposal after use.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01n)

Image (827bc01c D379 4266 A18c C7f904b76af3 01n)
An instructional diagram of a KEVZARA injection syringe showing labeled parts including the plunger, finger grip, label, expiry date, syringe body, needle cap, and needle. The syringe is marked with the KEVZARA brand name and dosage details in orange on the label portion.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01o)

Image (827bc01c D379 4266 A18c C7f904b76af3 01o)
An instructional illustration showing a hand holding a syringe and extracting medication from an opened package containing multiple syringes. The image depicts the process of preparing a subcutaneous injection, likely related to the KEVZARA injection solution product.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01p)

Image (827bc01c D379 4266 A18c C7f904b76af3 01p)
KEVZARA 200 mg/1.14 mL injection, solution label for subcutaneous use. The label shows the proprietary name KEVZARA with the generic name sarilumab below it, and the strength 200 mg/1.14 mL prominently displayed. Also visible are sections for lot number and expiration date. The product is labeled by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01q)

FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01r)

Image (827bc01c D379 4266 A18c C7f904b76af3 01r)
An illustration showing a KEVZARA (sarilumab) injection pen with a label indicating 150 mg/1.14 mL. The pen is depicted with an orange handle and black cover, alongside a clock diagram highlighting a 30-minute period, likely indicating injection duration or timing instructions.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01s)

Image (827bc01c D379 4266 A18c C7f904b76af3 01s)
An illustration showing recommended injection sites for subcutaneous administration. The highlighted areas include the upper arms, abdomen (excluding a 2-inch area around the navel), and the front of the thighs. The graphic indicates proper body locations for subcutaneous injections of KEVZARA (sarilumab) injection solution.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01t)

Image (827bc01c D379 4266 A18c C7f904b76af3 01t)
An illustration showing hands preparing a KEVZARA (sarilumab) injection, solution for subcutaneous administration. The image depicts removal of the syringe cap by pulling it off, highlighting proper handling of the prefilled syringe before injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01u)

Image (827bc01c D379 4266 A18c C7f904b76af3 01u)
An illustration showing a hand pinching the skin on an arm, demonstrating a technique likely related to subcutaneous injection administration.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01v)

Image (827bc01c D379 4266 A18c C7f904b76af3 01v)
An instructional illustration showing a hand administering a subcutaneous injection of KEVZARA (sarilumab) using a prefilled syringe. The syringe is held at a 45-degree angle, with the needle inserted into the skin, demonstrating proper injection technique for the subcutaneous route.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01w)

Image (827bc01c D379 4266 A18c C7f904b76af3 01w)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) injection pen, demonstrating the proper technique to activate the injection by pressing a button to deliver the subcutaneous injection dose.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01x)

Image (827bc01c D379 4266 A18c C7f904b76af3 01x)
An instructional illustration showing a hand administering a subcutaneous injection with an orange-labeled syringe. The syringe is positioned at an angle to the skin, indicating proper injection technique, consistent with a self-injection of KEVZARA (sarilumab) injection solution.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 01y)

Image (827bc01c D379 4266 A18c C7f904b76af3 01y)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) prefilled syringe for subcutaneous injection. The image depicts the process of removing a black needle cap from the syringe above a disposal container, indicated by orange arrows pointing downward.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 02)

Image (827bc01c D379 4266 A18c C7f904b76af3 02)
An illustration of a KEVZARA (sarilumab) 150 mg/1.14 mL pre-filled pen for subcutaneous injection. The pen features an orange label showing strength and product name, a window to view the solution inside, a yellow needle cover, and an orange safety cap. The pen is marked with areas for label and expiration date.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 03)

Image (827bc01c D379 4266 A18c C7f904b76af3 03)
KEVZARA (sarilumab) injection 150 mg/1.14 mL single-dose pre-filled pen for subcutaneous injection only. The label indicates Rx only and shows an NDC number 0024-5920-01. The labeler is Sanofi-Aventis U.S. LLC, with storage instructions to refrigerate.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 04)

Image (827bc01c D379 4266 A18c C7f904b76af3 04)
An instructional diagram showing two syringe views for KEVZARA injection solution. The top image indicates an unused syringe with a white background and a blue checkmark. The bottom image shows a used syringe with a yellow background and a red X mark, emphasizing proper syringe use by visual color cues.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 05)

Image (827bc01c D379 4266 A18c C7f904b76af3 05)
An instructional illustration showing the KEVZARA (sarilumab) 150 mg/1.14 mL prefilled syringe, used for subcutaneous injection. The image also includes a clock graphic indicating a 60-minute time period, likely related to timing instructions for use.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 06)

Image (827bc01c D379 4266 A18c C7f904b76af3 06)
Illustration showing recommended subcutaneous injection sites for KEVZARA (sarilumab) on the human body. Marked areas include the outer upper arms, the stomach area excluding a 2-inch radius around the navel, and the front of the thighs. These locations are highlighted in orange on a diagram of a person's front torso and legs, with blue underwear for reference.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 07)

Image (827bc01c D379 4266 A18c C7f904b76af3 07)
An instructional illustration depicting the removal of a yellow cap from the syringe tip by twisting and pulling it off, with directional arrows indicating the motion required.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 08)

Image (827bc01c D379 4266 A18c C7f904b76af3 08)
Instructional illustration showing a hand holding a KEVZARA injection pen at a 90-degree angle to the skin, demonstrating the correct technique for subcutaneous injection of sarilumab solution in a prefilled pen format.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 09)

Image (827bc01c D379 4266 A18c C7f904b76af3 09)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) 150 mg/1.14 mL injection pen poised above skin. The image highlights the pen's dose window with a label "first click" and a downward arrow indicating the direction to press the pen for subcutaneous injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 10)

Image (827bc01c D379 4266 A18c C7f904b76af3 10)
An instructional illustration showing a person using the KEVZARA (sarilumab) injection pen device. The image highlights holding the pen against the skin and a timer indicating to hold the injection for up to 15 seconds for proper administration.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 11)

Image (827bc01c D379 4266 A18c C7f904b76af3 11)
An instructional illustration showing the subcutaneous injection of KEVZARA (sarilumab) using an autoinjector. It depicts the device being pressed against the skin, with a highlighted note indicating a 'second click' event during administration.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 12)

Image (827bc01c D379 4266 A18c C7f904b76af3 12)
An instructional illustration showing a hand holding a KEVZARA (sarilumab) injection pen. The image depicts the pen positioned vertically above the skin with a green arrow pointing upwards, indicating the direction or step for administering the subcutaneous injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 13)

Image (827bc01c D379 4266 A18c C7f904b76af3 13)
An instructional illustration showing a hand holding a KEVZARA injection pen or syringe, about to be disposed of into a sharps container. The device label includes dosing information (200 mg/1.14 mL) and the KEVZARA brand name, indicating proper and safe disposal of the used injection device.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 14)

Image (827bc01c D379 4266 A18c C7f904b76af3 14)
KEVZARA 200 mg/1.14 mL pre-filled pen injection, solution for subcutaneous use. The pen includes a label displaying the drug name, strength, and usage instructions, a window to view the solution, a yellow needle cover, and an orange removable cap. The label also states storage instructions and shows space for expiration date and lot number.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 15)

Image (827bc01c D379 4266 A18c C7f904b76af3 15)
Label of KEVZARA (sarilumab) injection 200 mg/1.14 mL single-dose pre-filled pen for subcutaneous injection only. The label includes lot and expiration information and storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F). The product is labeled by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 16)

Image (827bc01c D379 4266 A18c C7f904b76af3 16)
An instructional illustration showing how to visually check a KEVZARA injection device before use. The top image with a clear, unused solution is marked with a green check, indicating the device is unused. The bottom image with a yellowed solution is marked with a red X, indicating the device has been used and should not be reused.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 17)

Image (827bc01c D379 4266 A18c C7f904b76af3 17)
An illustration showing a KEVZARA 150 mg/1.14 mL prefilled syringe for subcutaneous injection, labeled with dosage information and an orange safety cap. Next to it is a clock graphic indicating a 60-minute time period, likely representing an instruction or observation interval related to injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 18)

Image (827bc01c D379 4266 A18c C7f904b76af3 18)
An instructional illustration showing recommended injection sites for subcutaneous injection. Highlighted areas include the outer upper arms, abdomen (excluding a 2-inch area around the navel), and front thighs. A key indicates that the orange-colored areas represent appropriate injection sites.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 19)

Image (827bc01c D379 4266 A18c C7f904b76af3 19)
An instructional illustration showing the removal of a protective cap or cover from a syringe or injection pen. The image depicts the cap being twisted and pulled off, indicated by green arrows, as part of the preparation for subcutaneous injection.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 20)

Image (827bc01c D379 4266 A18c C7f904b76af3 20)
An instructional illustration showing a hand holding a KEVZARA injection pen at a 90-degree angle to the skin, demonstrating proper subcutaneous injection technique for the sarilumab solution, 150 mg/1.14 mL strength.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 21)

Image (827bc01c D379 4266 A18c C7f904b76af3 21)
An instructional illustration showing a hand holding a KEVZARA 150 mg/1.14 mL or 200 mg/1.14 mL subcutaneous injection device vertically and pressing it against the skin. A label highlights the action as the "first click," with a green arrow indicating downward pressure on the injection site.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 22)

Image (827bc01c D379 4266 A18c C7f904b76af3 22)
An illustration showing the use of a KEVZARA (sarilumab) injection device for subcutaneous administration. The image depicts a hand holding the injector against the skin with an adjacent timer indicating the injection should take up to 15 seconds.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 23)

Image (827bc01c D379 4266 A18c C7f904b76af3 23)
An instructional illustration showing the use of a KEVZARA injection device. The image depicts the device being pressed against the skin with a label reading "second click," indicating a step in the injection process.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 24)

Image (827bc01c D379 4266 A18c C7f904b76af3 24)
Illustration showing a hand holding a KEVZARA injection pen with visible partial label indicating 150 mg/1.14 mL strength, positioned with the needle end down toward the skin for subcutaneous injection, accompanied by a green arrow pointing upward to suggest needle removal or injection step.*
FDA Label Image

Image (827bc01c D379 4266 A18c C7f904b76af3 25)

Image (827bc01c D379 4266 A18c C7f904b76af3 25)
An instructional illustration showing a hand disposing of a KEVZARA 150 mg/1.14 mL or 200 mg/1.14 mL pre-filled injection pen into a sharps disposal container. The image demonstrates safe disposal of the used subcutaneous injection device for sarilumab by Sanofi-Aventis U.S. LLC.*
FDA Label Image

Principal Display Panel (150 mg/1.14 mL Syringe Carton)

Principal Display Panel (150 mg/1.14 mL Syringe Carton)
Packaging label for KEVZARA (sarilumab) injection, 150 mg/1.14 mL (131.6 mg/mL) solution for subcutaneous injection. The label indicates 2 single-dose pre-filled syringes per carton. Manufactured by Sanofi-Aventis U.S. LLC in collaboration with Regeneron. The label includes storage instructions, contents, and a barcode.*
FDA Label Image

Principal Display Panel (200 mg/1.14 mL Syringe Carton)

Principal Display Panel (200 mg/1.14 mL Syringe Carton)
Packaging label for KEVZARA (sarilumab) injection, 200 mg/1.14 mL (175.4 mg/mL) strength, presented as 2 single-dose pre-filled syringes for subcutaneous injection. The label includes storage instructions, carton contents, and manufacturer information by Sanofi-Aventis U.S. LLC and Regeneron. Prominent orange areas highlight the strength and dosage form.*
FDA Label Image

Principal Display Panel (150 mg/1.14 mL Pen Carton)

Principal Display Panel (150 mg/1.14 mL Pen Carton)
KEVZARA (sarilumab) injection 150 mg/1.14 mL (131.6 mg/mL) single-dose pre-filled pens carton. Contains 2 pre-filled pens for subcutaneous injection. Labeler is Sanofi-Aventis U.S. LLC. Packaging includes storage instructions, barcode, and medication guide warning. The design features the KEVZARA logo and dosing information on a white and orange background.*
FDA Label Image

Principal Display Panel (200 mg/1.14 mL Pen Carton)

Principal Display Panel (200 mg/1.14 mL Pen Carton)
Packaging label for KEVZARA (sarilumab) injection, 200 mg/1.14 mL (175.4 mg/mL) solution for subcutaneous injection, containing 2 single-dose pre-filled pens. The label mentions storage instructions, includes the NDC 0024-5922-01, and is labeled by Sanofi-Aventis U.S. LLC. The carton includes a medication guide, instructions for use, and warns that the enclosed medication guide is required for each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.